DOI QR코드

DOI QR Code

Does Zoledronic Acid Have Additive Effect on Suppression of Plasma Estrogen Levels ?

  • Published : 2013.01.31

Abstract

Keywords

References

  1. Pfeiler G, Königsberg R, Fesl C, et al (2011). Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol, 29, 2653-9. https://doi.org/10.1200/JCO.2010.33.2585
  2. Santini D, Vincenzi B, Galluzzo S, et al (2007). Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res, 13, 4482-6. https://doi.org/10.1158/1078-0432.CCR-07-0551
  3. Schech AJ, Nemieboka BE, Brodie AH (2012). Zoledronic acid inhibits aromatase activity and phosphorylation: Potential mechanism for additive zoledronic acid and letrozole drug interaction. J Steroid Biochem Mol Biol, 132, 195-202. https://doi.org/10.1016/j.jsbmb.2012.05.008
  4. Brufsky A, Harker WG, Beck JT, et al (2007). Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol, 25, 829-36. https://doi.org/10.1200/JCO.2005.05.3744
  5. Eidtmann H, de Boer R, Bundred N, et al (2010). Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol, 21, 2188-94. https://doi.org/10.1093/annonc/mdq217
  6. Folkerd EJ, Dixon JM, Renshaw L, A'Hern RP, Dowsett M (2012). Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol, 30, 2977-80. https://doi.org/10.1200/JCO.2012.42.0273
  7. Gnant M, Mlineritsch B, Luschin-Ebengreuth G (2008). Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol, 9, 840-9. https://doi.org/10.1016/S1470-2045(08)70204-3
  8. Gnant M, Mlineritsch B, Schippinger W, et al. (2009). Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med, 360, 679-91. https://doi.org/10.1056/NEJMoa0806285
  9. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al (2007). Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol, 25, 820-8. https://doi.org/10.1200/JCO.2005.02.7102
  10. Kunzmann V, Bauer E, Feurle J, et al (2000). Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood, 96, 384-92.